Ahmedabad-based Eris Lifesciences has announced a breakthrough step in expanding access to advanced diabetes care with the launch of its generic Semaglutide under the brand ‘SUNDAE’ in India.
Reinforcing its commitment as a responsible stakeholder in addressing the country’s growing diabetes burden, Eris is introducing SUNDAE in multi-dose vial formats at highly accessible pricing starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants.
This launch significantly improves affordability, bringing effective GLP-1 therapy within reach for nearly 70% of India’s diabetes patient population.
The company also plans to further enhance patient convenience and adoption with the introduction of a pen-device version in April priced at MRP of Rs 4,000, Rs 4,200 and Rs 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively.
Semaglutide, a GLP-1 receptor agonist, has emerged as a transformative therapy for Type 2 diabetes and weight management, driven by strong outcomes in glycemic control and weight reduction. With India’s rapidly growing diabetic population and rising awareness of obesity, GLP-1 therapies present a significant growth opportunity.
Eris has established a strong presence in diabetology through deep engagement with specialists across India. The addition of semaglutide further strengthens its advanced diabetes portfolio and expands its role in next-generation metabolic care.
